Review How Photobiomodulation could help with Dementia, Alzheimer's & Parkinson's diseases
In 2018, Dr Berman was invited to speak about how Photobiomodulation (Light Therapy) & Neurofeedback (brain mapping) could help those with Alzheimer's, Dementia, or Parkinson's. During this podcast, Dr Berman shares his experiences as a psychotherapist that helped him recognize how there could be potentially many neurological disorders that were caused by undiagnosed traumatic brain injury. Through this realization, he set to explore how he could combine brain mapping (using a QEEG) and photobiomodulation as a treatment for other neurological disorders like Alzheimer's, Dementia, and Parkinson's.
Photobiomodulation (light therapy) is the process of using Near Infrared Light to both stimulate blood flow in your brain and protein. This light is pulsed at a specific frequency between the range of 700 and 900 nanometers, and then a QEEG (brain mapping) is used to monitor the changes in a person's brain.
At the end of 2020, Dr. Berman completed his recruitment for study (granted by the National Institute of Health (NIH)) that will follow the progress of a 100 patients with with early to mid-stage dementia. In early 2021, he hopes to have published the results of this study.
IVERMECTIN TX for COVID 19
I want to share this important news about a treatment for COVID 19 that has been upgraded by CDC and has been shown to be quite helpful as a prophylactic and early intervention therapeutic intervention. This report is from our functional medicine colleagues at Health Revival Partners with whom we collaborate on all our cases where evaluation of underlying metabolic, infectious factors. They play a key role in our 3-pronged treatment approach of digital neurotherapeutics, photobiomodulation and functional medicine.
Recent evidence is proving that COVID19 causes serious white matter damage much like that caused by stroke. I am sharing this with everyone as it is quite clear that my not having sustained neurological injury from my experience with CV19 last April is due to my intensive use of transcranial photobiomodulation therapy. I treated myself with the Cognitolite device 2-4xdaiky for 5 weeks during the period I was infected and then 3-5 x / week thereafter. I also used 5 doses of clarithromycin, 2G vitC 3-4x/day, 5000iu D3, 50mcg zinc.
There is published evidence that this type of stimulation has improved healing rates against viruses eg, MRSA and improved cognitive cognitive functions of people struggling with various forms of dementia.
I encourage the use of near infrared LED light stimulation and am participating in several studies to further describe the mechanism of action.
see the equipment section of this website for several options including the Cognitolite now available for purchase.
This report underscores the importance of increasing efforts to recruit communities of color to participate in ongoing clinical trials of innovative dementia treatments. Quietmind Fdn. has succeeded in recruiting 12% of the forty subjects in it's most recent trial on the efficacy of twice-daily, self-administered, transcranial and intraocular near-infrared (1068nm) photobiomodulation therapy. We have to find ways to encourage greater participation from these communities in order to determine the disparities in response and therefor how best to modify treatment protocols to produce better clinical outcomes.
QMF will soon be initiating several home-based, self-administered, clinical trial protocols using different noninvasive, non-drug therapeutic applications of infrared-light and pulsed electromagnetic stimulation. Please contact us through the website or by phone (610) 940-0488 to inquire and enroll as there will be a limited number of subjects accepted.
January 5, 2021Disparities Persist in Dementia Risk of Black and White AdultsMary Stroka
More work is needed to identify and address modifiable sources of persistent racial disparities in US dementia prevalence.The ratio of dementia risk across non-Hispanic Black and White individuals in the United States does not appear to have changed between 2000 and 2016, researchers found in a study published in JAMA Neurology.
Several studies have reported that the risk of dementia is higher in non-Hispanic Black individuals than in non-Hispanic White individuals. Using data from the US Health and Retirement Study (HRS), a nationally representative study of adults aged 50 and older, the researchers sought to examine whether relative racial disparities in dementia in the US, both in terms of relative prevalence and relative incidence of dementia, changed from 2000 to 2016.
The researchers analyzed data from 9 HRS waves spanning 2000 through 2016. Each wave (which had a range of 6322 to 7579 eligible participants per wave) became a cross-sectional study to quantify racial disparities in the prevalence of dementia at 2-year intervals from 2000 through 2016. The researchers estimated trends in racial disparities over that time using the data from all 9 waves.
Subcohorts (which ranged in size from 5322 to 5961 participants) with 4 years of follow-up were nested within the larger longitudinal HRS to quantify racial disparities over calendar periods, with baseline years in 2000 to 2012. All subcohorts’ data was then combined.
Today’s Top Picks for You on Psychiatry Advisor
Teen Suicide Rate Quadrupled Over the Past DecadeDementia May Contribute to More Deaths Than Previously ThoughtPoor Dental Health May Increase Risk for Incident Dementia, MCI
Participants who had an algorithmic dementia diagnosis in the baseline year were excluded from subcohorts, and subcohort participants who did not have a diagnosis at the end of 2 waves of follow-up were censored.
The researchers conducted all analyses using the Expert Model, LASSO (least absolute shrinkage and selection operator), and Modified Hurd Algorithms, which predict dementia status based on sociodemographic characteristics, physical health, and cognitive health collected at HRS interview. All 3 algorithms were designed for use in HRS-based studies of racial and ethnic disparities in dementia by having similar out-of-sample sensitivity and specificity across non-Hispanic White and non-Hispanic Black subgroups.
The study authors applied HRS sampling weights to adjust for differential probability of inclusion and accounted for geographic stratification and clustering when estimating standard errors. Data from non-Hispanic Black and non-Hispanic White HRS participants who were aged 70 and older at each wave to whom they could assign an algorithmic dementia diagnosis were analyzed. Weighted regression models were used to estimate crude dementia prevalence ratios and to estimate and quantify time trends in dementia incidence. Race-specific distribution of age and sex in the year 2000 were standardized.
The Expert Model and LASSO algorithms classified an average of 20% of participants as having dementia while the Modified Hurd algorithm classified 18% of participants as having dementia. All 3 algorithms found that non-Hispanic Black participants had about a 1.5 to 1.9 times higher prevalence of dementia compared with non-Hispanic White participants in all waves in both crude and standardized estimates.
Overall, dementia prevalence declined with time in both crude and standardized estimates, and point estimates suggested a slight decline in the crude prevalence ratio comparing the groups in later years, but relative dementia prevalence across both groups did not change substantially over time. After age and sex standardization, there was no evidence of a shrinking racial disparity over time.
Across all subcohorts, non-Hispanic Black participants had an approximately 1.4 to 1.8 times higher incidence of dementia in comparison with non-Hispanic White participants. Analyses using the Expert Model or Modified Hurd algorithms to ascertain dementia status suggested no change over time, whereas analyses using the LASSO model suggested declining dementia incidence with time only in age- and sex-standardized analyses.
Limitations of the study included the use of an algorithm to ascertain dementia and the focus on the prevalence and incidence of the clinical syndrome of dementia rather than biomarker-based diagnoses of Alzheimer disease.
“Although our findings suggest stable or declining dementia risk overall, we found no evidence to suggest that relative racial disparities in dementia risk have narrowed between 2000 and 2016,” the authors said.
Power MC, Bennett EE, Turner RW, et al. Trends in relative incidence and prevalence of dementia across non-Hispanic Black and White individuals in the United States, 2000-2016. JAMA Neurol. Published online November 30, 2020. doi:10.1001/jamaneurol.2020.4471
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.